Human-recombinant ADAM10 (aa 214-672, lacking the pro-domain, R&D Systems 936-AD-020), mouse-recombinant ADAM10 (aa 19-673, including the pro-domain, Calbiochem PF124), ADAM10 pro-domain synthetic peptide (Abcam ab41165; 32 aa within the pro-domain, sequence not available because of property used as immunogen to generate the anti-ADAM10 pro-domain antibody), human-recombinant ADAM17 (aa 1-671, including the pro-domain, Calbiochem PF133) and human ceruloplasmin purified from plasma (Alexis Biochemicals, ALX-200-089) were spotted (200 ng each spot) onto nitrocellulose membrane and tested with the fraction of IgG purified from the sera of six Crc patients considered positive for the presence of auto-antibodies anti-ADAM10 and six patients considered negative. Membrane strips were incubated for 2 hr at 20°C with IgG purified from Crc patients sera (50 μg/ml of IgG working dilution) and reactivity revealed with
HRP-conjugated anti-human-IgG (Southern Biotechnology) followed by ECL reaction and film exposure. As controls, the reactivity of the rabbit anti-ADAM10 Ab (Abcam,
ab39153) that recognizes both mature and immature ADAM10, rabbit anti-ADAM10 pro-domain Ab (Abcam,
ab39178), rabbit anti-ADAM17 (Abcam,
ab39163) and sheep anti-ceruloplasmin (Abcam,
ab8813) were tested on the spotted proteins. Immunoreactivities were revealed as described above.
Álvarez-Fernández S.M., Barbariga M., Cannizzaro L., Cannistraci C.V., Hurley L., Zanardi A., Conti A., Sanvito F., Innocenzi A., Pecorelli N., Braga M, & Alessio M. (2016). Serological immune response against ADAM10 pro-domain is associated with favourable prognosis in stage III colorectal cancer patients. Oncotarget, 7(48), 80059-80076.